Krasniqi, E.
Sacconi, A.
Marinelli, D.
Pizzuti, L.
Mazzotta, M.
Sergi, D.
Capomolla, E.
Donzelli, S.
Carosi, M.
Bagnato, A.
Gamucci, T.
Tomao, S.
Natoli, C.
Marchetti, P.
Grassadonia, A.
Tinari, N.
De Tursi, M.
Vizza, E.
Ciliberto, G.
Landi, L.
Cappuzzo, F.
Barba, M. http://orcid.org/0000-0001-9050-2917
Blandino, G.
Vici, P.
Funding for this research was provided by:
Scientific Direction of Regina Elena National Cancer Institute
Article History
Received: 27 October 2020
Accepted: 26 April 2021
First Online: 13 July 2021
Declarations
:
: The study protocol was approved by the IRE’s Ethics Committee.
: Not applicable.
: SA, MD, MM, SD, CE, DS, CM, BA, TS, GA, TN, DTM, VE, CG, LL, CF, BM, and BG declare no conflicts of interest. KE received fees for scientific advice for Eisai and Novartis. PL received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees from Roche, Pfizer, Novartis, Gentili. MP had an advisory role for BMS, Roche Genentech, MSD, Novartis, Amgen, Merck Serono, Pierre Fabre, and Incyte. GT received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees/advisory boards from Roche, Pfizer, Novartis, Gentili, Lilly. NC received travel grants/personal fees from Pfizer, EISAI, Novartis, Merck Sharp & Dohme, AstraZeneca. VP received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees/advisory boards from Roche, Pfizer, Novartis, Gentili, Lilly.